Medical Condition News

RSS

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Cancer patients with annual incomes below $50,000 less likely to participate in clinical trials

Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

GE Healthcare signed an agreement with Affibody AB to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

4 Jun 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

New evidence of important role of next-generation sequencing in cancer treatment

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced results from two studies using next-generation sequencing (NGS) to provide actionable information about genomic tumor alterations in individual patients' cancers across all solid tumor types.

2 Jun 2012

Patients with normal lipoprotein(a) levels may retain risk of atherosclerosis due to elevated LDL-P number

LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced results from a clinical study demonstrating that patients with normal levels of lipoprotein(a) may retain significant risk of atherosclerosis due to an elevated low density lipoprotein particle (LDL-P) number.

2 Jun 2012

Researchers uncover fundamental properties of key molecular signaling system using optical tweezers

By using a laser microbeam technology called optical tweezers, UC Irvine and UCLA researchers have uncovered fundamental properties of a key molecular signaling system involved with development, cancer and cardiovascular disease.

2 Jun 2012

Study finds natural ruminant trans fats not harmful

Canadian scientists are joining with international colleagues to lead new insights into the health implications of different types of trans fat.

2 Jun 2012

Socioeconomic status of patient linked to choice of treatment

Though it would seem logical, cancer patients don't always choose therapies with the best chance for survival-cost and side effects are also major considerations. Little has been known about the extent to which cost and side effects influence a patient's treatment decision. Now, new findings by Fox Chase Cancer Center researchers reveals that a patient's socioeconomic status, more than any other characteristic-such as age or disease site-is predictive of whether he or she will favor high efficacy, low cost or low toxicity when choosing a treatment.

2 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

NIH awards $1.9M grant to study genetic control of cell migration

Developmental biologists Dominique Alfandari and Hélène Cousin at the University of Massachusetts Amherst recently received a five-year, $1.9 million grant from the U.S. National Institutes of Health to investigate craniofacial development in a frog model to better understand genetic control of cell migration.

2 Jun 2012

High costs can limit access to potentially life-saving technology

More than one-fifth of people who have received referrals to test for cancer-causing genes say they will only undergo testing if their insurance covers the cost-just as more insurers are instituting cost-sharing for medical services like genetic testing, according to new findings from Fox Chase Cancer Center in Philadelphia released at this year's 2012 Annual Meeting of the American Society of Clinical Oncology on Saturday, June 2.

2 Jun 2012

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

Two tumor suppressor genes function to disrupt overactive EGFR signaling

Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment.

2 Jun 2012

Medical Condition News

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Cancer patients with annual incomes below $50,000 less likely to participate in clinical trials

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Study reveals why GBM is highly resistant to current chemotherapies

New evidence of important role of next-generation sequencing in cancer treatment

Patients with normal lipoprotein(a) levels may retain risk of atherosclerosis due to elevated LDL-P number

Researchers uncover fundamental properties of key molecular signaling system using optical tweezers

Study finds natural ruminant trans fats not harmful

Socioeconomic status of patient linked to choice of treatment

New molecular test panel to enhance reliability of thyroid biopsy testing

NIH awards $1.9M grant to study genetic control of cell migration

High costs can limit access to potentially life-saving technology

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two tumor suppressor genes function to disrupt overactive EGFR signaling

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News